We are pleased to announce that Prof. Enrico Mini joined Innovative Medicines & Omics as Editor-in-Chief.
Name: Prof. Enrico Mini
Email: enrico.mini@unifi.it
Affiliation: Emeritus Professor of Medical Oncology, Department of Health Sciences, University of Florence, Florence, Italy
Homepage: https://www.researchgate.net/profile/Enrico-Mini
Research Interests: Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism
Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance.
Prof. Mini is the author of more than 190 original articles in international peer-reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses.
In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London).
Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology.
We warmly welcome Prof. Enrico Mini in his new role as Editor-in-Chief, and we look forward to his leading Innovative Medicines & Omics to many more milestones.